|
|
 |
|
Viewing report
|
|
|
|
Autoimmune Disease Series: Strategies for Success in the Challenging Sj�gren's Syndrome Market
Decision Resources, Inc., Dec 2008, Pages: 33
Introduction
Sjögren’s syndrome (SS) is one of the most prevalent autoimmune diseases. SS has no cure, and most rheumatologists rely on polypharmacy to sufficiently control patients’ symptoms. New agents in development for SS offer novel mechanisms of action for the disease. However, these agents will face challenges, including the dominating presence of low-cost generic and OTC treatments, in obtaining patient share.
Get the Answers You Need to Shape Your Strategy
- SS is an autoimmune disease that affects multiple organs in the body. What is known about the causes of SS? How is the disease diagnosed? What are the most common symptoms of the disease?
- SS is one of the most prevalent autoimmune diseases. What is the prevalence of SS? How will the patient population grow over the next ten years?
- SS has no cure. What treatments are available for SS? What do rheumatologists choose as first line therapy? What are the strengths and drawbacks of available treatments?
- The large SS patient population has prompted significant development for the disease. What agents are in development for SS? How do these agents compare with existing therapies? What level of adoption should drug developers anticipate for emerging agents?
Scope
- Primary research: We surveyed more than 50 U.S. rheumatologists to ascertain their current prescribing practices and their opinions of emerging agents.
- Overview: Disease definition, etiology, diagnosis, symptoms.
- Epidemiology: Patient population for 2007 through 2017.
- Current therapies: Allergan/Inspire Pharmaceuticals’ Restasis, Eisai/Kissei Pharmaceutical’s Salagen, Daiichi Sankyo’s Evoxac, punctal plugs, hydroxychloroquine, methotrexate, azathioprine
- Emerging therapies: Biogen Idec/Genentech/Chugai Pharmaceutical/Zenyaku Kogyo/Roche’s Rituxan/MabThera, UCB/Immunomedic’s epratuzumab, Centocor/Schering-Plough/Mitsubishi Tanabe’s Remicade, Amgen/Wyeth/Takeda Pharmaceutical’s Enbrel, Allergan/Santen/Inspire Pharmaceuticals’ Prolacria, Ista Pharmaceuticals’ ecabet sodium, Acucela/Otsuka Pharmaceutical’s rebamipide, TorreyPines Therapeutics’ NGX-267
- Autoimmune Disease Series: In 2007, sales of agents used to treat autoimmune disorders exceeded $20 billion. Still, for many of the more than 80 identified autoimmune disorders, treatment options are limited. Targeting underserved autoimmune diseases offers drug developers the opportunity to introduce their agents into the autoimmune market while taking advantage of minimal competition and an expedited regulatory process. This report is part of the Autoimmune Disease Series, which provides critical market information, including disease prevalence, profiles
Customers who bought this item also bought
Orphan Disease Series - Glaucoma: Can Orphan-Drug Status Offer an Entry into a Mature Market?
Stakeholder Opinions: Non-Hodgkins Lymphoma - Is there room to emulate Rituxans success?
|
|
|
|
